CAMK1

Summary

CAMK1 (calcium/calmodulin dependent protein kinase I, HGNC:1459) is a protein-coding gene on chromosome 3p25.3, encoding Calcium/calmodulin-dependent protein kinase type 1 (Q14012). Calcium/calmodulin-dependent protein kinase that operates in the calcium-triggered CaMKK-CaMK1 signaling cascade and, upon calcium influx, regulates transcription activators activity, cell cycle, hormone production, cell differentiation, actin filament organization and neurite o….

Calcium/calmodulin-dependent protein kinase I is expressed in many tissues and is a component of a calmodulin-dependent protein kinase cascade. Calcium/calmodulin directly activates calcium/calmodulin-dependent protein kinase I by binding to the enzyme and indirectly promotes the phosphorylation and synergistic activation of the enzyme by calcium/calmodulin-dependent protein kinase I kinase.

Source: NCBI Gene 8536 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 76 total
• Druggable target: yes — 19 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_003656

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1459
Approved symbol	CAMK1
Name	calcium/calmodulin dependent protein kinase I
Location	3p25.3
Locus type	gene with protein product
Status	Approved
Aliases	CaMKI, CaMKI-alpha
Ensembl gene	ENSG00000134072
Ensembl biotype	protein_coding
OMIM	604998
Entrez	8536

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000256460, ENST00000397277, ENST00000411972, ENST00000421120, ENST00000482803, ENST00000496534, ENST00000856591, ENST00000856592, ENST00000856593, ENST00000856594, ENST00000856595, ENST00000856596, ENST00000856597, ENST00000962076, ENST00000962077

RefSeq mRNA: 1 — MANE Select: NM_003656 NM_003656

CCDS: CCDS2582

Canonical transcript exons

ENST00000256460 — 12 exons

Exon	Start	End
ENSE00001135141	9767667	9767781
ENSE00001165098	9769832	9769947
ENSE00001954612	9757347	9757621
ENSE00003466603	9759672	9759750
ENSE00003493373	9759488	9759575
ENSE00003511946	9761631	9761757
ENSE00003541626	9763139	9763213
ENSE00003541736	9762914	9763052
ENSE00003567355	9765759	9765890
ENSE00003570225	9760656	9760768
ENSE00003593007	9761461	9761536
ENSE00003687552	9757729	9757846

Expression profiles

Bgee: expression breadth ubiquitous, 208 present calls, max score 97.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.8621 / max 290.7500, expressed in 1696 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
40976	16.5125	1693
40977	0.3496	154

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	97.23	gold quality
right adrenal gland	UBERON:0001233	97.16	gold quality
left adrenal gland cortex	UBERON:0035825	96.97	gold quality
left adrenal gland	UBERON:0001234	96.80	gold quality
adrenal cortex	UBERON:0001235	96.50	gold quality
right frontal lobe	UBERON:0002810	95.47	gold quality
prefrontal cortex	UBERON:0000451	94.87	gold quality
nucleus accumbens	UBERON:0001882	94.87	gold quality
caudate nucleus	UBERON:0001873	94.78	gold quality
monocyte	CL:0000576	94.49	gold quality
amygdala	UBERON:0001876	94.44	gold quality
adrenal gland	UBERON:0002369	94.39	gold quality
left uterine tube	UBERON:0001303	94.22	gold quality
mononuclear cell	CL:0000842	93.95	gold quality
putamen	UBERON:0001874	93.88	gold quality
omental fat pad	UBERON:0010414	93.87	gold quality
peritoneum	UBERON:0002358	93.80	gold quality
leukocyte	CL:0000738	93.73	gold quality
cingulate cortex	UBERON:0003027	93.73	gold quality
anterior cingulate cortex	UBERON:0009835	93.63	gold quality
left coronary artery	UBERON:0001626	93.38	gold quality
adipose tissue of abdominal region	UBERON:0007808	93.38	gold quality
right ovary	UBERON:0002118	93.37	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.33	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.32	gold quality
granulocyte	CL:0000094	93.17	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.07	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.81	gold quality
popliteal artery	UBERON:0002250	92.76	gold quality
lower esophagus	UBERON:0013473	92.76	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.62
E-ENAD-17	no	15.41

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
ERVW-1	Activation
HDAC5	Activation

Upstream regulators (CollecTRI, top): GLI2, NR5A1

miRNA regulators (miRDB)

35 targeting CAMK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-141-5P	99.57	67.86	897
HSA-MIR-6832-3P	99.52	70.44	1726
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-297	99.40	69.58	1418
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-3149	98.77	67.13	1639
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-12120	98.05	68.44	1768

Literature-anchored findings (GeneRIF, showing 15)

• CaMKI is involved in angiotensin II and K(+) stimulation of CYP11B2 transcription and the capacity of the adrenal to produce aldosterone (PMID:12193581)
• we cloned a novel calmodulin-kinase (CaM-KIdelta) from HeLa cells and characterized its activation mechanism. CaM-KIdelta exhibits Ca(2+)/CaM-dependent activity that is enhanced in vitro by phosphorylation of its Thr180 by CaM-K kinase (CaM-KK)alpha (PMID:12935886)
• calcium/calmodulin-dependent protein kinase I regulates of cyclin D1/Cdk4 complexes (PMID:14754892)
• Calcium/calmodulin-dependent protein kinase I inhibits neuronal nitric-oxide synthase activity through serine 741 phosphorylation (PMID:15251453)
• Dioxin-mediated up-regulation of aryl hydrocarbon receptor target genes is dependent on the calcium/calmodulin/CaMKIalpha pathway. (PMID:18089838)
• variants in doublecortin- and calmodulin kinase like 1, a gene up-regulated by BDNF, have roles in memory and general cognitive abilities (PMID:19844571)
• CaMKI was significantly upregulated in adrenal adenomas. (PMID:21249615)
• structures of three CaMKIalpha truncates in apo form and in complexes with ATP (PMID:23028635)
• Fbxl12-induced CaMKI degradation attenuates p27 phosphorylation at these sites in early G1 and iii) activation of CaMKI during G1 transition followed by p27 phosphorylation appears to be upstream to other p27 phosphorylation events (PMID:23707388)
• It is one of Ca(2+)-sensing proteins and substantial age- and Alzheimer disease(AD)-related alterations in Ca(2+)-sensing proteins most likely contribute to selective vulnerability of basal forebrain cholinergic neurons to degeneration in AD. (PMID:24461366)
• CAMK1 functional regulation subnetwork in hepatocellular carcinoma (PMID:24825433)
• this study suggests that the tightly linked regulatory loop comprised of the SIK2-PP2A and CaMKI and PME-1 networks may function in fine-tuning cell proliferation and stress response. (PMID:24841198)
• Barettin has inhibitory activity against two protein kinases related to inflammation, namely the receptor-interacting serine/threonine kinase 2 (RIPK2) and calcium/calmodulin-dependent protein kinase 1alpha (CAMK1alpha). (PMID:26466644)
• The mRNA expressions of PPP3CB and MEF2C were significantly up-regulated, and CAMK1 and PPP3R1 were significantly down-regulated in mitral regurgitation(MR) patients compared to normal subjects. Moreover, MR patients had significantly increased mRNA levels of PPP3CB, MEF2C and PLCE1 compared to aortic valve disease patients (PMID:27907007)
• Expression of CAMK1 and its association with clinicopathologic characteristics in pancreatic cancer. (PMID:33342045)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	camk1b	ENSDARG00000029474
danio_rerio	camk1a	ENSDARG00000060116
danio_rerio		ENSDARG00000116980
mus_musculus	Camk1	ENSMUSG00000030272
rattus_norvegicus	Camk1	ENSRNOG00000021781
caenorhabditis_elegans		WBGENE00000553

Paralogs (22): CAMKK1 (ENSG00000004660), CAMK1G (ENSG00000008118), CAMK2B (ENSG00000058404), CAMK2A (ENSG00000070808), MYLK2 (ENSG00000101306), CAMKK2 (ENSG00000110931), STK11 (ENSG00000118046), STK33 (ENSG00000130413), PNCK (ENSG00000130822), DCLK1 (ENSG00000133083), MYLK3 (ENSG00000140795), CAMK2D (ENSG00000145349), MYLK4 (ENSG00000145949), PSKH2 (ENSG00000147613), CAMK2G (ENSG00000148660), PHKG2 (ENSG00000156873), PSKH1 (ENSG00000159792), DCLK3 (ENSG00000163673), CAMKV (ENSG00000164076), PHKG1 (ENSG00000164776), DCLK2 (ENSG00000170390), CAMK1D (ENSG00000183049)

Protein

Protein identifiers

Calcium/calmodulin-dependent protein kinase type 1 — Q14012 (reviewed: Q14012)

Alternative names: CaM kinase I, CaM kinase I alpha

All UniProt accessions (5): B0YIY3, C9JES6, Q14012, F8W6S9, H7C071

UniProt curated annotations — full annotation on UniProt →

Function. Calcium/calmodulin-dependent protein kinase that operates in the calcium-triggered CaMKK-CaMK1 signaling cascade and, upon calcium influx, regulates transcription activators activity, cell cycle, hormone production, cell differentiation, actin filament organization and neurite outgrowth. Recognizes the substrate consensus sequence [MVLIF]-x-R-x(2)-[ST]-x(3)-[MVLIF]. Regulates axonal extension and growth cone motility in hippocampal and cerebellar nerve cells. Upon NMDA receptor-mediated Ca(2+) elevation, promotes dendritic growth in hippocampal neurons and is essential in synapses for full long-term potentiation (LTP) and ERK2-dependent translational activation. Downstream of NMDA receptors, promotes the formation of spines and synapses in hippocampal neurons by phosphorylating ARHGEF7/BETAPIX on ‘Ser-694’, which results in the enhancement of ARHGEF7 activity and activation of RAC1. Promotes neuronal differentiation and neurite outgrowth by activation and phosphorylation of MARK2 on ‘Ser-91’, ‘Ser-92’, ‘Ser-93’ and ‘Ser-294’. Promotes nuclear export of HDAC5 and binding to 14-3-3 by phosphorylation of ‘Ser-259’ and ‘Ser-498’ in the regulation of muscle cell differentiation. Regulates NUMB-mediated endocytosis by phosphorylation of NUMB on ‘Ser-276’ and ‘Ser-295’. Involved in the regulation of basal and estrogen-stimulated migration of medulloblastoma cells through ARHGEF7/BETAPIX phosphorylation. Is required for proper activation of cyclin-D1/CDK4 complex during G1 progression in diploid fibroblasts. Plays a role in K(+) and ANG2-mediated regulation of the aldosterone synthase (CYP11B2) to produce aldosterone in the adrenal cortex. Phosphorylates EIF4G3/eIF4GII. In vitro phosphorylates CREB1, ATF1, CFTR, MYL9 and SYN1/synapsin I.

Subunit / interactions. Monomer. Interacts with XPO1. Interacts with MARK2, ARHGEF7/BETAPIX and GIT1.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Widely expressed. Expressed in cells of the zona glomerulosa of the adrenal cortex.

Post-translational modifications. Phosphorylated by CaMKK1 and CaMKK2 on Thr-177. Polybiquitinated by the E3 ubiquitin-protein ligase complex SCF(FBXL12), leading to proteasomal degradation.

Activity regulation. Activated by Ca(2+)/calmodulin. Binding of calmodulin results in conformational change that relieves intrasteric autoinhibition and allows phosphorylation of Thr-177 within the activation loop by CaMKK1 or CaMKK2. Phosphorylation of Thr-177 results in several fold increase in total activity. Unlike CaMK4, is unable to exhibit autonomous activity after Ca(2+)/calmodulin activation.

Domain organisation. The autoinhibitory domain overlaps with the calmodulin binding region and interacts in the inactive folded state with the catalytic domain as a pseudosubstrate.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CaMK subfamily.

RefSeq proteins (1): NP_003647* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site

Pfam: PF00069

Enzyme classification (BRENDA):

• EC 2.7.11.17 — Ca2+/calmodulin-dependent protein kinase (BRENDA: 38 organisms, 300 substrates, 137 inhibitors, 35 Km, 17 kcat entries)

Substrate kinetics (BRENDA)

12 substrates with measured Km, best-characterized 12. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0071–178.29	13
BIOTINYLATED THR-ARG-SER-ALA-ILE-ARG-ARG-ALA-SER	0.0064–0.0158	4
GST-TAGGED GLUN2A	6.05–11.75	2
GST-TAGGED GLUN2B	0.35–5.93	2
MAP2	0.0007–0.0008	2
CALDESMON	0.0049	1
HISTONE IIIS	0.0445	1
LYS-LYS-ALA-LEU-ARG-ARG-GLN-GLU-ALA-VAL-ASP-ALA-	0.063	1
MICROTUBULE ASSOCIATED PROTEIN 2	0.0016	1
SYNTIDE-2	0.02	1
SYNTIDE-2 PEPTIDE	0.0221	1
MYELIN BASIC PROTEIN	—	0

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (43 total): helix 15, strand 8, turn 4, mutagenesis site 3, sequence variant 2, region of interest 2, binding site 2, modified residue 2, chain 1, domain 1, cross-link 1, short sequence motif 1, active site 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
4FG8	X-RAY DIFFRACTION	2.2
4FG9	X-RAY DIFFRACTION	2.4
4FGB	X-RAY DIFFRACTION	2.6
4FG7	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14012-F1	79.87	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 141 (proton acceptor)

Ligand- & substrate-binding residues (2): 26–34; 49

Post-translational modifications (3): 59, 177, 363

Mutagenesis-validated functional residues (3):

Position	Phenotype
49	catalytically inactive form; prevents cdk4 activation.
177	loss of activation by camkk1.
177	partial activation in absence of camkk1.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-9617324	Negative regulation of NMDA receptor-mediated neuronal transmission
R-HSA-9619229	Activation of RAC1 downstream of NMDARs
R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission
R-HSA-112315	Transmission across Chemical Synapses
R-HSA-112316	Neuronal System
R-HSA-438064	Post NMDA receptor activation events
R-HSA-442755	Activation of NMDA receptors and postsynaptic events

MSigDB gene sets: 261 (showing top): GOBP_DENDRITE_DEVELOPMENT, BIOCARTA_FMLP_PATHWAY, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_DENDRITIC_SPINE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_REGULATION_OF_PROTEIN_EXPORT_FROM_NUCLEUS, GOBP_NEUROGENESIS, MEF2_02, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_TRANSPORT, GOBP_NUCLEAR_TRANSPORT, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_CELL_JUNCTION_ORGANIZATION

GO Biological Process (20): nucleocytoplasmic transport (GO:0006913), signal transduction (GO:0007165), nervous system development (GO:0007399), positive regulation of neuron projection development (GO:0010976), cell differentiation (GO:0030154), regulation of protein localization (GO:0032880), intracellular signal transduction (GO:0035556), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of protein export from nucleus (GO:0046827), regulation of synapse organization (GO:0050807), regulation of muscle cell differentiation (GO:0051147), positive regulation of muscle cell differentiation (GO:0051149), positive regulation of synapse structural plasticity (GO:0051835), positive regulation of syncytium formation by plasma membrane fusion (GO:0060143), positive regulation of dendritic spine development (GO:0060999), protein phosphorylation (GO:0006468), regulation of neuron projection development (GO:0010975), negative regulation of protein binding (GO:0032091), regulation of protein binding (GO:0043393), positive regulation of protein serine/threonine kinase activity (GO:0071902)

GO Molecular Function (11): protein serine/threonine kinase activity (GO:0004674), calcium/calmodulin-dependent protein kinase activity (GO:0004683), calmodulin binding (GO:0005516), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), catalytic activity (GO:0003824), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), cytosol (GO:0005829), postsynaptic density (GO:0014069)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Activation of NMDA receptors and postsynaptic events	2
Post NMDA receptor activation events	1
Transmission across Chemical Synapses	1
Neuronal System	1
Neurotransmitter receptors and postsynaptic signal transmission	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	3
neuron projection development	2
intracellular anatomical structure	2
muscle cell differentiation	2
positive regulation of cellular component organization	2
protein serine/threonine kinase activity	2
protein kinase activity	2
cellular anatomical structure	2
nuclear transport	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
system development	1
regulation of neuron projection development	1
positive regulation of cell projection organization	1
cellular developmental process	1
intracellular protein localization	1
regulation of localization	1
signal transduction	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
protein export from nucleus	1
positive regulation of nucleocytoplasmic transport	1
regulation of protein export from nucleus	1
positive regulation of intracellular protein transport	1
regulation of synapse structure or activity	1
synapse organization	1
regulation of cellular component organization	1
regulation of cell differentiation	1
positive regulation of cell differentiation	1
regulation of muscle cell differentiation	1
regulation of synapse structural plasticity	1
syncytium formation by cell-cell fusion	1
regulation of syncytium formation by plasma membrane fusion	1
positive regulation of developmental process	1
dendritic spine development	1
regulation of dendritic spine development	1

Protein interactions and networks

STRING

1491 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CAMK1	CALM1	P02593	916
CAMK1	CALML4	Q96GE6	845
CAMK1	CALML3	P27482	844
CAMK1	CALML5	Q9NZT1	844
CAMK1	CALML6	Q8TD86	834
CAMK1	ARPP21	Q9UBL0	637
CAMK1	CYP11B2	P19099	632
CAMK1	CREB1	P16220	603
CAMK1	KCNN2	Q9H2S1	550
CAMK1	SYN2	Q92777	537
CAMK1	HSP90AB1	P08238	515
CAMK1	HSP90AA1	P07900	513
CAMK1	MEF2A	Q02078	502
CAMK1	KCNMA1	Q12791	490
CAMK1	PPP2CA	P05323	460

IntAct

80 interactions, top by confidence:

A	B	Type	Score
PHF19	EED	psi-mi:“MI:0914”(association)	0.730
ATXN1	CAMK1	psi-mi:“MI:0915”(physical association)	0.720
CAMK1D	CAMK1	psi-mi:“MI:0915”(physical association)	0.620
CALM1	CAMK1	psi-mi:“MI:0407”(direct interaction)	0.590
IL16	CAMK1	psi-mi:“MI:0915”(physical association)	0.560
HTT	CAMK1	psi-mi:“MI:0915”(physical association)	0.560
EPHA1	EXOC5	psi-mi:“MI:0914”(association)	0.530
CCDC106	NEFM	psi-mi:“MI:0914”(association)	0.530
CDO1	DBT	psi-mi:“MI:0914”(association)	0.530
HTR2C	KLRG2	psi-mi:“MI:0914”(association)	0.530
CER1	POTEF	psi-mi:“MI:0914”(association)	0.530
SAMTOR	PER1	psi-mi:“MI:0914”(association)	0.530
PHF19	EPOP	psi-mi:“MI:0914”(association)	0.530
ANKRD22	ESYT2	psi-mi:“MI:0914”(association)	0.530
PTPN6	CAMK1	psi-mi:“MI:0915”(physical association)	0.400
CAMK1		psi-mi:“MI:0915”(physical association)	0.400
CAMK1	BLK	psi-mi:“MI:0915”(physical association)	0.400
CAMK1	PIK3R3	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (115): CAMK1 (Affinity Capture-MS), CAMK1 (Affinity Capture-MS), CAMK1 (Affinity Capture-MS), CAMK1 (Affinity Capture-MS), CAMK1 (Affinity Capture-MS), BLK (Affinity Capture-MS), CAMK1 (Biochemical Activity), PPME1 (Biochemical Activity), CAMK1 (Two-hybrid), CAMK1 (Two-hybrid), CAMK1 (Affinity Capture-MS), CAMK1 (Affinity Capture-MS), CAMK1 (Affinity Capture-MS), CAMK1 (Affinity Capture-MS), CAMK1 (Affinity Capture-MS)

ESM2 similar proteins: A8X6H4, O70150, O75582, P10665, P11275, P11798, P18652, P18653, P18654, P28583, P51812, Q13557, Q14012, Q15349, Q2HJF7, Q38869, Q38871, Q38872, Q39016, Q42396, Q54CY9, Q54SJ5, Q5F3L1, Q5R4K3, Q5RCC4, Q5ZKI0, Q63450, Q63531, Q6DEH3, Q6GLS4, Q6P2M8, Q6PFQ0, Q6PHZ2, Q7TPS0, Q869W6, Q8BW96, Q8IU85, Q8RWL2, Q8VDF3, Q91YS8

Diamond homologs: A0A2I0BVG8, A0A509AFG4, A0A509AHB6, A0A509ALV6, A0A509AQE6, A0A5K1K8H0, A0AAR7, A5A7I7, A5A7I8, A8X6H4, O15865, O49717, O70150, P25323, P28582, P28583, P34101, P49101, P53681, P53682, P53683, P53684, P62343, P62344, P62345, P93759, Q06850, Q0D715, Q0DYK7, Q10KY3, Q14012, Q1PE17, Q1PFH8, Q2QQR2, Q2QVG8, Q2QX45, Q38868, Q38869, Q38870, Q38871

SIGNOR signaling

22 interactions.

A	Effect	B	Mechanism
CAMK1	down-regulates	NUMB	phosphorylation
CAMK1	unknown	EIF4G3	phosphorylation
CAMK1	“up-regulates activity”	GCM1	phosphorylation
RAP1A	“up-regulates activity”	CAMK1
CAMK1	“down-regulates activity”	PPME1	phosphorylation
CAMK1	unknown	KRT18	phosphorylation
CAMK1	“up-regulates activity”	PPME1	phosphorylation
PPM1F	“down-regulates activity”	CAMK1	dephosphorylation
CAMK1	“up-regulates activity”	ARHGEF2	phosphorylation
CAMK1	down-regulates	HDAC5	phosphorylation
FBXL12	“down-regulates quantity”	CAMK1	ubiquitination
CAMK1	“up-regulates activity”	CDKN1B	phosphorylation
CAMK1	“up-regulates activity”	ATF1	phosphorylation
CAMK1	“up-regulates activity”	CAMK1	phosphorylation
CAMK1	“down-regulates activity”	NOS1	phosphorylation
CAMK1	“down-regulates activity”	SYN1	phosphorylation
CAMKK2	“up-regulates activity”	CAMK1	phosphorylation
CAMKK1	“up-regulates activity”	CAMK1	phosphorylation
CAMK1	“up-regulates activity”	DNM1L	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	53
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1811 predictions. Top by Δscore:

Variant	Effect	Δscore
3:9757853:T:C	acceptor_gain	1.0000
3:9757853:T:TC	acceptor_gain	1.0000
3:9757860:CA:C	acceptor_gain	1.0000
3:9757861:A:AC	acceptor_gain	1.0000
3:9757861:A:C	acceptor_gain	1.0000
3:9757861:A:T	acceptor_gain	1.0000
3:9757862:T:C	acceptor_gain	1.0000
3:9757862:T:TC	acceptor_gain	1.0000
3:9759483:CTCA:C	donor_loss	1.0000
3:9759484:TCA:T	donor_loss	1.0000
3:9759485:CACCT:C	donor_loss	1.0000
3:9759670:A:AC	donor_gain	1.0000
3:9759671:C:CC	donor_gain	1.0000
3:9759746:TTTGG:T	acceptor_gain	1.0000
3:9759747:TTGG:T	acceptor_gain	1.0000
3:9759748:TGG:T	acceptor_gain	1.0000
3:9759749:GG:G	acceptor_gain	1.0000
3:9759751:C:CC	acceptor_gain	1.0000
3:9759760:C:CT	acceptor_gain	1.0000
3:9759760:C:T	acceptor_gain	1.0000
3:9759761:A:T	acceptor_gain	1.0000
3:9759765:C:CT	acceptor_gain	1.0000
3:9761457:TTACA:T	donor_loss	1.0000
3:9761459:A:AC	donor_gain	1.0000
3:9761460:C:CA	donor_gain	1.0000
3:9761460:CA:C	donor_gain	1.0000
3:9761460:CAA:C	donor_gain	1.0000
3:9761460:CAAG:C	donor_gain	1.0000
3:9761460:CAAGA:C	donor_gain	1.0000
3:9761532:AGGGG:A	acceptor_gain	1.0000

AlphaMissense

2448 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:9759673:A:G	W275R	1.000
3:9759673:A:T	W275R	1.000
3:9760664:G:A	S246F	1.000
3:9760677:A:G	W242R	1.000
3:9760677:A:T	W242R	1.000
3:9760747:G:C	F218L	1.000
3:9760747:G:T	F218L	1.000
3:9760749:A:G	F218L	1.000
3:9760751:G:T	P217H	1.000
3:9760760:C:A	G214V	1.000
3:9760760:C:T	G214D	1.000
3:9760766:A:G	L212P	1.000
3:9761479:C:T	G205D	1.000
3:9761480:C:G	G205R	1.000
3:9761489:A:G	W202R	1.000
3:9761489:A:T	W202R	1.000
3:9761495:C:G	D200H	1.000
3:9761637:A:G	Y184H	1.000
3:9761648:C:T	G180E	1.000
3:9761701:G:C	D162E	1.000
3:9761701:G:T	D162E	1.000
3:9761702:T:A	D162V	1.000
3:9761702:T:C	D162G	1.000
3:9761702:T:G	D162A	1.000
3:9761703:C:G	D162H	1.000
3:9761744:A:G	L148P	1.000
3:9761747:A:G	L147P	1.000
3:9761749:A:C	N146K	1.000
3:9761749:A:T	N146K	1.000
3:9761751:T:C	N146D	1.000

dbSNP variants (sampled 300 via entrez): RS1000255179 (3:9769578 C>T), RS1000349198 (3:9769287 C>A,T), RS1000523584 (3:9764563 C>T), RS1000716628 (3:9770583 G>A,C), RS1001226359 (3:9769638 T>G), RS1001436923 (3:9762597 T>G), RS1001531576 (3:9767469 C>T), RS1001594385 (3:9763783 C>T), RS1001808155 (3:9761160 C>G,T), RS1001847020 (3:9765552 C>T), RS1001931268 (3:9765161 A>G), RS1002026457 (3:9764934 T>C), RS1002158550 (3:9769904 A>T), RS1003304691 (3:9770974 T>C), RS1003376079 (3:9759110 G>C,T)

Disease associations

OMIM: gene MIM:604998 | disease phenotypes: MIM:144700

GenCC curated gene-disease

Mondo (1): nonpapillary renal cell carcinoma (MONDO:0007763)

Orphanet (1): Hereditary clear cell renal cell carcinoma (Orphanet:422526)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2493 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

19 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 156,708 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL2103743	TOFACITINIB CITRATE	4	1,672
CHEMBL221959	TOFACITINIB	4	10,408
CHEMBL477772	PAZOPANIB	4	15,540
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL603469	LESTAURTINIB	3
CHEMBL1230609	FORETINIB	2	3,096
CHEMBL1721885	SU-014813	2	363
CHEMBL1980297	ILORASERTIB	2	581
CHEMBL1980715	LAUROGUADINE	2	294
CHEMBL475251	R-406	2	762
CHEMBL521851	PICTILISIB	2	6,071
CHEMBL572878	TOZASERTIB	2	2,998
CHEMBL1908397	KW-2449	1	622
CHEMBL574738	AST-487	1	451

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1052133	CAMK1, OGG1		0.00	0
rs293795	CAMK1, OGG1		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CAMK1 family

Binding affinities (BindingDB)

7 measured of 7 human assays (7 total across all organisms); most potent 7 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Staurosporine	KD	1.7 nM
PKC-412	KD	190 nM
1-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea	KD	1400 nM
5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide	KD	2600 nM
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide	KD	2900 nM
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	KD	3500 nM
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile	KD	5000 nM

ChEMBL bioactivities

126 potent at pChembl≥5 of 128 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.00	IC50	1	nM	CHEMBL4635883
8.70	IC50	2	nM	CHEMBL4640712
8.61	IC50	2.43	nM	STAUROSPORINE
8.52	IC50	3.02	nM	STAUROSPORINE
8.52	IC50	3	nM	CHEMBL4635883
8.48	IC50	3.33	nM	STAUROSPORINE
8.09	IC50	8.2	nM	CHEMBL4635883
7.96	IC50	11	nM	CHEMBL4635883
7.90	Ki	12.59	nM	CHEMBL1980995
7.64	IC50	23	nM	CHEMBL4635883
7.57	Kd	27	nM	STAUROSPORINE
7.52	Kd	30	nM	STAUROSPORINE
7.50	Ki	31.62	nM	CHEMBL2000271
7.10	Ki	79.43	nM	CHEMBL1984162
7.00	Ki	100	nM	CHEMBL1974870
6.90	Ki	125.9	nM	CHEMBL2002726
6.89	Kd	130	nM	LESTAURTINIB
6.70	Ki	199.5	nM	CHEMBL2004716
6.64	Kd	230	nM	R-406
6.60	Ki	251.2	nM	CHEMBL1971029
6.60	Ki	251.2	nM	CHEMBL1991063
6.50	Ki	316.2	nM	CHEMBL1987034
6.50	Ki	316.2	nM	CHEMBL1965836
6.50	Ki	316.2	nM	CHEMBL1993661
6.40	Ki	398.1	nM	CHEMBL1987054
6.33	Kd	470	nM	RUXOLITINIB
6.30	Ki	501.2	nM	CHEMBL1998159
6.20	Ki	631	nM	CHEMBL1974328
6.10	Ki	794.3	nM	CHEMBL1977041
6.10	Ki	794.3	nM	CHEMBL1241473
6.01	Kd	970	nM	SUNITINIB
6.00	IC50	1000	nM	TP-030n
6.00	Ki	1000	nM	CHEMBL504950
6.00	Ki	1000	nM	ILORASERTIB
5.96	Kd	1100	nM	TAE-684
5.92	Kd	1200	nM	TOFACITINIB CITRATE
5.92	Kd	1200	nM	TOFACITINIB
5.90	Ki	1259	nM	CHEMBL1972584
5.90	Ki	1259	nM	CHEMBL2002479
5.90	Ki	1259	nM	CHEMBL2001751
5.90	Ki	1259	nM	CHEMBL1979577
5.90	Ki	1259	nM	CHEMBL1990885
5.85	Kd	1400	nM	KW-2449
5.80	Kd	1600	nM	FEDRATINIB
5.80	Ki	1585	nM	CHEMBL2002165
5.80	Ki	1585	nM	CHEMBL2000832
5.80	Ki	1585	nM	CHEMBL1965988
5.80	Ki	1585	nM	CHEMBL2000685
5.80	Ki	1585	nM	CHEMBL1979883
5.80	Ki	1585	nM	CHEMBL1967720

PubChem BioAssay actives

45 with measured affinity, of 1622 total; 29 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(3S)-3-aminopiperidin-1-yl]-4-[[2,6-di(propan-2-yl)-4-pyridinyl]amino]pyrimidine-5-carboxamide	1668858: Inhibition of human CAMK1A using KKALRRQETVDAL as substrate in presence of [gamma-33P]-ATP by hotspot kinase assay	ic50	0.0010	uM
2-[(3S)-3-aminopiperidin-1-yl]-4-[3,5-bis(2-cyanopropan-2-yl)anilino]pyrimidine-5-carboxamide	1668858: Inhibition of human CAMK1A using KKALRRQETVDAL as substrate in presence of [gamma-33P]-ATP by hotspot kinase assay	ic50	0.0020	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	2198154: Inhibition of human CAMK1a using KKALRRQETVDAL as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by radiometric Hot-SpotSM Kinase assay	ic50	0.0024	uM
Abemaciclib	1551240: Inhibition of wild-type human full length CAMK1A (M1 to L370 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	ki	0.0100	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	507852: Binding affinity to CAMK1	kd	0.1300	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	624922: Binding constant for CAMK1 kinase domain	kd	0.2300	uM
Ruxolitinib	624922: Binding constant for CAMK1 kinase domain	kd	0.4700	uM
Sunitinib	436009: Binding constant for full-length CAMK1	kd	0.9700	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624922: Binding constant for CAMK1 kinase domain	kd	1.1000	uM
Tofacitinib	624922: Binding constant for CAMK1 kinase domain	kd	1.2000	uM
[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone	624922: Binding constant for CAMK1 kinase domain	kd	1.4000	uM
Fedratinib	624922: Binding constant for CAMK1 kinase domain	kd	1.6000	uM
N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide	624922: Binding constant for CAMK1 kinase domain	kd	1.9000	uM
Midostaurin	436009: Binding constant for full-length CAMK1	kd	2.0000	uM
Pazopanib	436009: Binding constant for full-length CAMK1	kd	2.1000	uM
(3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one	624922: Binding constant for CAMK1 kinase domain	kd	2.1000	uM
4-[4-[3-[4-[(propan-2-ylamino)methyl]anilino]-1H-pyrazol-5-yl]phenyl]benzene-1,3-diol	301979: Inhibition of CAMK1	ic50	2.1300	uM
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	436009: Binding constant for full-length CAMK1	kd	3.0000	uM
1-pentyl-4-(2-phenylmethoxyphenyl)imidazol-2-amine;hydrochloride	1734144: Inhibition of wild-type human CAMK1alpha using KKALRRQETVDAL peptide as substrate in presence of Ca2+ calmodulin and [gamma-33P]-ATP by radiometric hotspot kinase assay	ic50	3.0000	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	436009: Binding constant for full-length CAMK1	kd	3.3000	uM
2-N-(3,5-dichlorophenyl)-4-N-[4-(dimethylamino)cyclohexyl]-5-(3-methyl-1,2-oxazol-5-yl)pyrimidine-2,4-diamine	721400: Inhibition of CAMK1 (unknown origin) in presence of ATP	ic50	3.8800	uM
14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one	256643: Average Binding Constant for CAMK1; NA=Not Active at 10 uM	kd	4.1000	uM
(4-hydroxypiperidin-1-yl)-[4-[[4-[4-(3-methylsulfonylpropoxy)indol-1-yl]pyrimidin-2-yl]amino]cyclohexyl]methanone	769531: Binding affinity to CAMK1 (unknown origin)	kd	4.3000	uM
4-[2-(1H-indazol-4-yl)-6-[(4-methylsulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine	624922: Binding constant for CAMK1 kinase domain	kd	4.7000	uM
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate	624922: Binding constant for CAMK1 kinase domain	kd	5.9000	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	624922: Binding constant for CAMK1 kinase domain	kd	5.9000	uM
4-N-[5-(diethylamino)pentan-2-yl]-2-[(E)-2-(2,4,6-trichlorophenyl)ethenyl]quinazoline-4,6-diamine	1452760: Inhibition of CaMK1alpha (unknown origin)	ic50	6.9000	uM
N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide	624922: Binding constant for CAMK1 kinase domain	kd	7.0000	uM
N-[(2S,3R,4R,6R,18S)-18-hydroxy-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide	507852: Binding affinity to CAMK1	kd	7.4000	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
beta-lapachone	decreases expression	1
sodium bichromate	decreases expression	1
afimoxifene	decreases response to substance	1
sodium arsenite	decreases expression, increases abundance	1
W 7	decreases reaction, increases phosphorylation	1
cobaltous chloride	decreases expression	1
nickel sulfate	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
tamibarotene	increases expression	1
1,2-bis(2-aminophenoxy)ethane N,N,N’,N’-tetraacetic acid acetoxymethyl ester	decreases reaction, increases phosphorylation	1
KN 93	decreases activity	1
CGP 52608	affects binding, increases reaction	1
STO 609	increases activity, increases phosphorylation	1
bisphenol S	increases expression	1
jinfukang	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	affects cotreatment, increases expression	1
Diuron	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1

ChEMBL screening assays

324 unique, capped per target: 322 binding, 2 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1004136	Binding	Inhibition of CAMK1 at 1 uM relative to control	Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. — J Med Chem
CHEMBL1963816	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CAMK1	PubChem BioAssay data set

Cellosaurus cell lines

4 cell lines: 3 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7LI	Ubigene A-549 CAMK1 KO	Cancer cell line	Male
CVCL_D8I9	Ubigene HCT 116 CAMK1 KO	Cancer cell line	Male
CVCL_D9AS	Ubigene HEK293 CAMK1 KO	Transformed cell line	Female
CVCL_D9Z6	Ubigene HeLa CAMK1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00414765	PHASE4	COMPLETED	Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
NCT00777504	PHASE4	UNKNOWN	Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
NCT00930345	PHASE4	TERMINATED	Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
NCT01206764	PHASE4	COMPLETED	A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
NCT01266837	PHASE4	COMPLETED	Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
NCT02056587	PHASE4	COMPLETED	Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
NCT02338570	PHASE4	TERMINATED	Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
NCT02596035	PHASE4	COMPLETED	An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
NCT02982954	PHASE4	COMPLETED	A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
NCT05949424	PHASE4	UNKNOWN	OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT07028125	PHASE4	RECRUITING	Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
NCT07405086	PHASE4	RECRUITING	Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
NCT00033904	PHASE3	COMPLETED	Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
NCT00126178	PHASE3	TERMINATED	Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
NCT00291369	PHASE3	COMPLETED	Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
NCT00326898	PHASE3	COMPLETED	Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
NCT00410124	PHASE3	COMPLETED	RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
NCT00474786	PHASE3	COMPLETED	Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
NCT00478114	PHASE3	COMPLETED	Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
NCT00606632	PHASE3	COMPLETED	Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
NCT00606866	PHASE3	COMPLETED	MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
NCT00631371	PHASE3	COMPLETED	Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
NCT00732914	PHASE3	COMPLETED	Sequential Study to Treat Renal Cell Carcinoma
NCT00869011	PHASE3	UNKNOWN	Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
NCT00930033	PHASE3	COMPLETED	Clinical Trial to Assess the Importance of Nephrectomy
NCT01030783	PHASE3	COMPLETED	A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
NCT01076010	PHASE3	COMPLETED	An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
NCT01198158	PHASE3	TERMINATED	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
NCT01223027	PHASE3	COMPLETED	Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
NCT01224288	PHASE3	ACTIVE_NOT_RECRUITING	Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
NCT01235962	PHASE3	COMPLETED	A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
NCT01265810	PHASE3	COMPLETED	Caphosol in Oral Mucositis Due to Targeted Therapy
NCT01265901	PHASE3	COMPLETED	IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
NCT01481870	PHASE3	UNKNOWN	Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
NCT01575548	PHASE3	ACTIVE_NOT_RECRUITING	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
NCT01582672	PHASE3	TERMINATED	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
NCT01613846	PHASE3	COMPLETED	Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
NCT01762592	PHASE3	WITHDRAWN	REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
NCT01865747	PHASE3	COMPLETED	A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
NCT02231749	PHASE3	COMPLETED	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)